# Correction: Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma

**Authors:** Yao Liang, Osamu Maeda, Chiaki Kondo, Kazuki Nishida, Yuichi Ando

PMC · DOI: 10.1371/journal.pone.0330099 · PLOS One · 2025-08-11

## Full-text entities

- **Genes:** KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845] {aka 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A}, STK11 (serine/threonine kinase 11) [NCBI Gene 6794] {aka LKB1, PJS, hLKB1}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, KEAP1 (kelch like ECH associated protein 1) [NCBI Gene 9817] {aka INrf2, KLHL19}
- **Diseases:** lung adenocarcinoma (MESH:D000077192)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12338798/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC12338798/full.md

---
Source: https://tomesphere.com/paper/PMC12338798